Evidence map›Paper›PMID 26252777›Full record

Trial reportPloS one2015

Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.

Hong-Mei Yan, Ming-Feng Xia, Yan Wang, Xin-Xia Chang, Xiu-Zhong Yao, Sheng-Xiang Rao, Meng-Su Zeng, Yin-Fang Tu, Ru Feng, Wei-Ping Jia and 4 more

3 registry-linked trialsOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 122 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
122citing papers in PubMed, 14 pooled it
9.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00633282 phase2completednot on this map

Role of Pioglitazone and Berberine in Treatment of Non-alcoholic Fatty Liver Disease(NAFLD) Patients With Impaired Glucose Regulation or Type 2 Diabetes Mellitus

TypeinterventionalSponsorXin GaoRan2008 to 2011Enrolled184ConditionsNonalcoholic Fatty Liver DiseaseArmsLife style intervention, pioglitazone, berberine
NCT03198572 phase4unknown statusnot on this mapstarted 2017, after this paper: background citation

Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial

TypeinterventionalSponsorFudan UniversityRan2017 to 2024Enrolled120ConditionsNon-alcoholic SteatohepatitisArmsLifestyle intervention, Placebo, Berberine
NCT05647915 phase4completednot on this mapstarted 2023, after this paper: background citation

Assess the Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals with Obesity and Non-alcoholic Fatty Liver Disease

TypeinterventionalSponsorChina National Center for Cardiovascular DiseasesRan2023 to 2024Enrolled337ConditionsObesity, Obesity, Abdominal, NAFLDArmsBerberine plus lifestyle intervention, Placebo plus lifestyle intervention
3 · Its place in the literature

Who cites it

122 citing papers in PubMed, 14 syntheses or guidelines pooled it, 225 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Review
  19. Article
  20. Review

62 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Hong-Mei YanDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Ming-Feng XiaDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yan WangInstitute of Materia Medica, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing, 100050, China.
Xin-Xia ChangDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Xiu-Zhong YaoDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Sheng-Xiang RaoDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Meng-Su ZengDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yin-Fang TuDepartment of Endocrinology and Metabolism, The Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, 200233, China.
Ru FengInstitute of Materia Medica, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing, 100050, China.
Wei-Ping JiaDepartment of Endocrinology and Metabolism, The Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, 200233, China.
Jun LiuDepartment of Endocrinology and Metabolism, The Fifth People's Hospital, Fudan University, Shanghai, 200240, China.
Wei DengSchool of public health, Fudan University, Shanghai, 200032, China.
Jian-Dong JiangInstitute of Materia Medica, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing, 100050, China.
Xin GaoDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNFudan University · CNSun Yat-sen University · CNShanghai Sixth People's Hospital · CNZhongshan Hospital · CNThe First Affiliated Hospital, Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesA randomized, parallel controlled, open-label clinical trial was conducted to evaluate the effect of a botanic compound berberine (BBR) on NAFLD.

methodsA randomized, parallel controlled, open-label clinical trial was conducted in three medical centers (NIH Registration number: NCT00633282). A total of 184 eligible patients with NAFLD were enrolled and randomly received (i) lifestyle intervention (LSI), (ii) LSI plus pioglitazone (PGZ) 15mg qd, and (iii) LSI plus BBR 0.5g tid, respectively, for 16 weeks. Hepatic fat content (HFC), serum glucose and lipid profiles, liver enzymes and serum and urine BBR concentrations were assessed before and after treatment. We also analyzed hepatic BBR content and expression of genes related to glucose and lipid metabolism in an animal model of NAFLD treated with BBR.

resultsAs compared with LSI, BBR treatment plus LSI resulted in a significant reduction of HFC (52.7% vs 36.4%, p = 0.008), paralleled with better improvement in body weight, HOMA-IR, and serum lipid profiles (all p<0.05). BBR was more effective than PGZ 15mg qd in reducing body weight and improving lipid profile. BBR-related adverse events were mild and mainly occurred in digestive system. Serum and urine BBR concentrations were 6.99ng/ml and 79.2ng/ml, respectively, in the BBR-treated subjects. Animal experiments showed that BBR located favorably in the liver and altered hepatic metabolism-related gene expression.

conclusionBBR ameliorates NAFLD and related metabolic disorders. The therapeutic effect of BBR on NAFLD may involve a direct regulation of hepatic lipid metabolism.

trial registrationClinicalTrials.gov NCT00633282.

Indexed as

AdiposityAdministration, OralAnimalsBerberineBlood GlucoseBody WeightDiet, High-FatDisease Models, AnimalEnergy MetabolismFemaleGene Expression RegulationHumansLiverMaleMetabolomeMiddle AgedBerberineBlood Glucose

Identifiers

PMID26252777
PMCPMC4529214
OpenAlexW2211572047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.